-
- We have global guidelines on how patient access should be considered before and after launch of a new medicine.
- The price of our medicines aims to reflect their overall value to patients and society, and take account of our duty to deliver value to shareholders.
Despite significant advances in healthcare in recent decades, many diseases are still under-diagnosed or not well treated, or there is not yet an effective therapy. Continued innovation is required to address these unmet medical needs. At the same time, the growing demand for healthcare, driven by people living longer, increasing populations and the emergence of new economies, means ever greater pressure on the payers’ budgets.
At AstraZeneca, our challenge is to balance the associated downward pressure on the price of medicines with the cost of the continued innovation that brings benefit for patients and society. Read more about how we price our medicines and protect our intellectual property. Innovative medicines also bring economic as well as therapeutic benefit, helping to contribute to the economic development of the communities in which we operate.
We also recognise that we have a role to play in improving health in the developing world, where often the lack of effective healthcare systems, including the lack of healthcare professionals, means that the availability of medicines is not always the primary challenge.
The content of this page was externally assured by Bureau Veritas, February 2009.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 02:22 GMT
Detailed share price